These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 1699280)

  • 1. Metabolism and action of fludarabine phosphate.
    Plunkett W; Huang P; Gandhi V
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):3-17. PubMed ID: 1699280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Deoxynucleotide pool depletion and sustained inhibition of ribonucleotide reductase and DNA synthesis after treatment of human lymphoblastoid cells with 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) adenine.
    Xie KC; Plunkett W
    Cancer Res; 1996 Jul; 56(13):3030-7. PubMed ID: 8674058
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cellular and clinical pharmacology of fludarabine.
    Gandhi V; Plunkett W
    Clin Pharmacokinet; 2002; 41(2):93-103. PubMed ID: 11888330
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5'-triphosphate.
    Parker WB; Shaddix SC; Chang CH; White EL; Rose LM; Brockman RW; Shortnacy AT; Montgomery JA; Secrist JA; Bennett LL
    Cancer Res; 1991 May; 51(9):2386-94. PubMed ID: 1707752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporation of fludarabine and 1-beta-D-arabinofuranosylcytosine 5'-triphosphates by DNA polymerase alpha: affinity, interaction, and consequences.
    Gandhi V; Huang P; Chapman AJ; Chen F; Plunkett W
    Clin Cancer Res; 1997 Aug; 3(8):1347-55. PubMed ID: 9815818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of 2-F-ara-A (9-beta-D-arabinofuranosyl-2-fluoroadenine) in cancer patients during the phase I clinical investigation of fludarabine phosphate.
    Malspeis L; Grever MR; Staubus AE; Young D
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):18-32. PubMed ID: 1699279
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity.
    Huang P; Chubb S; Plunkett W
    J Biol Chem; 1990 Sep; 265(27):16617-25. PubMed ID: 1697861
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolism and actions of 2-chloro-9-(2-deoxy-2-fluoro-beta-D- arabinofuranosyl)-adenine in human lymphoblastoid cells.
    Xie C; Plunkett W
    Cancer Res; 1995 Jul; 55(13):2847-52. PubMed ID: 7540950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro cytotoxic effects of fludarabine (2-F-ara-A) in combination with commonly used antileukemic agents by isobologram analysis.
    Kano Y; Akutsu M; Tsunoda S; Suzuki K; Ichikawa A; Furukawa Y; Bai L; Kon K
    Leukemia; 2000 Mar; 14(3):379-88. PubMed ID: 10720130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fludarabine infusion potentiates arabinosylcytosine metabolism in lymphocytes of patients with chronic lymphocytic leukemia.
    Gandhi V; Kemena A; Keating MJ; Plunkett W
    Cancer Res; 1992 Feb; 52(4):897-903. PubMed ID: 1737352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of c-Jun kinase in the apoptotic response to nucleoside analogue-induced DNA damage.
    Sampath D; Plunkett W
    Cancer Res; 2000 Nov; 60(22):6408-15. PubMed ID: 11103806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determination of drug synergism between the tyrosine kinase inhibitors NSC 680410 (adaphostin) and/or STI571 (imatinib mesylate, Gleevec) with cytotoxic drugs against human leukemia cell lines.
    Avramis IA; Laug WE; Sausville EA; Avramis VI
    Cancer Chemother Pharmacol; 2003 Oct; 52(4):307-18. PubMed ID: 12827297
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of fludarabine in hematological malignancies.
    Montillo M; Ricci F; Tedeschi A
    Expert Rev Anticancer Ther; 2006 Sep; 6(9):1141-61. PubMed ID: 17020450
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Minimum dose of fludarabine for the maximal modulation of 1-beta-D-arabinofuranosylcytosine triphosphate in human leukemia blasts during therapy.
    Gandhi V; Estey E; Du M; Keating MJ; Plunkett W
    Clin Cancer Res; 1997 Sep; 3(9):1539-45. PubMed ID: 9815841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of primer RNA formation in CCRF-CEM leukemia cells by fludarabine triphosphate.
    Catapano CV; Chandler KB; Fernandes DJ
    Cancer Res; 1991 Apr; 51(7):1829-35. PubMed ID: 1706219
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Action of 9-beta-D-arabinofuranosyl-2-fluoroadenine on RNA metabolism.
    Huang P; Plunkett W
    Mol Pharmacol; 1991 Apr; 39(4):449-55. PubMed ID: 1708088
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the actions of 9-beta-D-arabinofuranosyl-2-fluoroadenine and 9-beta-D-arabinofuranosyladenine on target enzymes from mouse tumor cells.
    White EL; Shaddix SC; Brockman RW; Bennett LL
    Cancer Res; 1982 Jun; 42(6):2260-4. PubMed ID: 7042080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of fludarabine on pharmacokinetics and pharmacodynamics of cytarabine: implications for a continuous infusion schedule.
    Seymour JF; Huang P; Plunkett W; Gandhi V
    Clin Cancer Res; 1996 Apr; 2(4):653-8. PubMed ID: 9816215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic basis of arabinonucleoside selectivity for human leukemic T- and B-lymphoblasts.
    Verhoef V; Fridland A
    Cancer Res; 1985 Aug; 45(8):3646-50. PubMed ID: 2410098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia.
    Gandhi V; Estey E; Du M; Nowak B; Keating MJ; Plunkett W
    Clin Cancer Res; 1995 Feb; 1(2):169-78. PubMed ID: 9815970
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.